Send us Feedback

Eli Lilly and Company (LLY)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

LLY » Topics » Our Intellectual Property Portfolio

This excerpt taken from the LLY 10-K filed Feb 22, 2010.
Our Intellectual Property Portfolio
We consider intellectual property protection for certain products, processes, and uses—particularly those products discussed below—to be important to our operations. For many of our products, in addition to the compound patent we hold other patents on manufacturing processes, formulations, or uses that may extend exclusivity beyond the expiration of the product patent.
 
The most relevant U.S. patent protection, together with expected expiration, for our major marketed products is as follows:
 
  •  Alimta is protected by a compound patent (2016).
 
  •  Byetta is protected by a patent covering its use in treating type 2 diabetes (2017).
 
  •  Cialis is protected by compound and use patents (2017).
 
  •  Cymbalta is protected by a compound patent (2013).
 
  •  Effient is protected by a compound patent (2017).
 
  •  Evista is protected by patents on the treatment and prevention of osteoporosis (2012 and 2014), and its dosage form (2017)1. Evista for use in breast cancer risk reduction is protected by orphan drug exclusivity (2014).
 
  •  Gemzar is protected by a compound patent (November 2010) and a patent covering its antineoplastic use (2013)1.
 
  •  Humalog is protected by a compound patent (2013).
 
  •  Strattera is protected by a patent covering its use in treating attention deficit-hyperactivity disorder (2016).
 
  •  Zyprexa is protected by a compound patent (October 2011).
 
1 The Evista dosage form patent and Gemzar use patent have been held invalid by federal district courts, and we have appealed those decisions. For more information, see Item 7, “Management’s Discussion and Analysis—Legal and Regulatory Matters.”
 
Worldwide, we sell all of our major products under trademarks that we consider in the aggregate to be important to our operations. Trademark protection varies throughout the world, with protection continuing in some countries as long as the mark is used, and in other countries as long as it is registered. Registrations are normally for fixed but renewable terms.
 
 
5

 

These excerpts taken from the LLY 10-K filed Feb 27, 2009.
Our Intellectual Property Portfolio
 
We consider intellectual property protection for certain products, processes, and uses − particularly those products discussed below − to be important to our operations. For many of our products, in addition to the compound patent we hold other patents on manufacturing processes, formulations, or uses that may extend exclusivity beyond the expiration of the product patent.
 
The most relevant U.S. patent protection, together with expected expiration, for our major marketed products is as follows:
 
  •   Alimta is protected by a compound patent (2016).
 
  •   Byetta is protected by a patent covering its use in treating type 2 diabetes (2017).
 
  •   Cialis is protected by compound and use patents (2017).
 
  •   Cymbalta is protected by a compound patent (2013).
 
  •   Evista is protected by patents on the treatment and prevention of osteoporosis (2012 and 2014), and its dosage form (2017). Evista for use in breast cancer risk reduction is protected by orphan drug exclusivity (2014).
 
  •   Gemzar is protected by a compound patent (2010) and a patent covering its antineoplastic use (2013).
 
  •   Humalog is protected by a compound patent (2013).
 
  •   Strattera is protected by a patent covering its use in treating attention deficit-hyperactivity disorder (2016).
 
  •   Zyprexa is protected by a compound patent (2011).
 
Worldwide, we sell all of our major products under trademarks that we consider in the aggregate to be important to our operations. Trademark protection varies throughout the world, with protection continuing in some countries as long as the mark is used, and in other countries as long as it is registered. Registrations are normally for fixed but renewable terms.
 
Our
Intellectual Property Portfolio


 



We consider intellectual property protection for certain
products, processes, and uses − particularly those
products discussed below − to be important to our
operations. For many of our products, in addition to the
compound patent we hold other patents on manufacturing
processes, formulations, or uses that may extend exclusivity
beyond the expiration of the product patent.


 



The most relevant U.S. patent protection, together with
expected expiration, for our major marketed products is as
follows:


 
































































































  •  
Alimta is protected by a compound patent (2016).
 
  •  
Byetta is protected by a patent covering its use in
treating type 2 diabetes (2017).
 
  •  
Cialis is protected by compound and use patents (2017).
 
  •  
Cymbalta is protected by a compound patent (2013).
 
  •  
Evista is protected by patents on the treatment and
prevention of osteoporosis (2012 and 2014), and its dosage form
(2017). Evista for use in breast cancer risk reduction is
protected by orphan drug exclusivity (2014).
 
  •  
Gemzar is protected by a compound patent (2010) and
a patent covering its antineoplastic use (2013).
 
  •  
Humalog is protected by a compound patent (2013).
 
  •  
Strattera is protected by a patent covering its use in
treating attention deficit-hyperactivity disorder (2016).
 
  •  
Zyprexa is protected by a compound patent (2011).


 



Worldwide, we sell all of our major products under trademarks
that we consider in the aggregate to be important to our
operations. Trademark protection varies throughout the world,
with protection continuing in some countries as long as the mark
is used, and in other countries as long as it is registered.
Registrations are normally for fixed but renewable terms.


 




These excerpts taken from the LLY 10-K filed Oct 21, 2008.
Our Intellectual Property Portfolio
 
We consider intellectual property protection for certain products, processes, and uses – particularly those products discussed below – to be important to our operations. For many of our products, in addition to the


-4-

Table of Contents

compound patent we hold other patents on manufacturing processes, formulations, or uses that may extend exclusivity beyond the expiration of the product patent.
 
The most relevant U.S. patent protection, together with expected expiration, for our major marketed products is as follows:
 
  •   Alimta is protected by a compound patent (2016).
 
  •   Byetta is protected by a patent covering its use in treating type 2 diabetes (2017).
 
  •   Cialis is protected by compound and use patents (2017).
 
  •   Cymbalta is protected by a compound patent (2013) and a composition patent (2014).
 
  •   Evista is protected by patents on the treatment and prevention of osteoporosis (2012 and 2014), and its dosage form (2017). Evista for use in breast cancer risk reduction is protected by orphan drug exclusivity (2014).
 
  •   Gemzar is protected by a compound patent (2010) and a patent covering its antineoplastic use (2013).
 
  •   Humalog is protected by a compound patent (2013).
 
  •   Strattera is protected by a patent covering its use in treating attention deficit-hyperactivity disorder (2016).
 
  •   Xigris is protected by a product patent (2015).
 
  •   Zyprexa is protected by a compound patent (2011).
 
Worldwide, we sell all of our major products under trademarks that we consider in the aggregate to be important to our operations. Trademark protection varies throughout the world, with protection continuing in some countries as long as the mark is used, and in other countries as long as it is registered. Registrations are normally for fixed but renewable terms.
 
Our
Intellectual Property Portfolio


 



We consider intellectual property protection for certain
products, processes, and uses – particularly those
products discussed below – to be important to our
operations. For many of our products, in addition to the





-4-




Table of Contents






compound patent we hold other patents on manufacturing
processes, formulations, or uses that may extend exclusivity
beyond the expiration of the product patent.


 



The most relevant U.S. patent protection, together with
expected expiration, for our major marketed products is as
follows:


 










































































































  •  
Alimta is protected by a compound patent (2016).
 
  •  
Byetta is protected by a patent covering its use in
treating type 2 diabetes (2017).
 
  •  
Cialis is protected by compound and use patents
(2017).
 
  •  
Cymbalta is protected by a compound patent
(2013) and a composition patent (2014).
 
  •  
Evista is protected by patents on the treatment and
prevention of osteoporosis (2012 and 2014), and its dosage form
(2017). Evista for use in breast cancer risk reduction is
protected by orphan drug exclusivity (2014).
 
  •  
Gemzar is protected by a compound patent
(2010) and a patent covering its antineoplastic use (2013).
 
  •  
Humalog is protected by a compound patent (2013).
 
  •  
Strattera is protected by a patent covering its use
in treating attention deficit-hyperactivity disorder (2016).
 
  •  
Xigris is protected by a product patent (2015).
 
  •  
Zyprexa is protected by a compound patent (2011).


 



Worldwide, we sell all of our major products under trademarks
that we consider in the aggregate to be important to our
operations. Trademark protection varies throughout the world,
with protection continuing in some countries as long as the mark
is used, and in other countries as long as it is registered.
Registrations are normally for fixed but renewable terms.


 




These excerpts taken from the LLY 10-K filed Feb 29, 2008.
Our Intellectual Property Portfolio
 
We consider intellectual property protection for certain products, processes, and uses – particularly those products discussed below – to be important to our operations. For many of our products, in addition to the


-4-

 

compound patent we hold other patents on manufacturing processes, formulations, or uses that may extend exclusivity beyond the expiration of the product patent.
 
The most relevant U.S. patent protection, together with expected expiration, for our major marketed products is as follows:
 
  •   Alimta is protected by a compound patent (2016).
 
  •   Byetta is protected by a patent covering its use in treating type 2 diabetes (2017).
 
  •   Cialis is protected by compound and use patents (2017).
 
  •   Cymbalta is protected by a compound patent (2013) and a composition patent (2014).
 
  •   Evista is protected by patents on the treatment and prevention of osteoporosis (2012 and 2014), and its dosage form (2017). Evista for use in breast cancer risk reduction is protected by orphan drug exclusivity (2014).
 
  •   Gemzar is protected by a compound patent (2010) and a patent covering its antineoplastic use (2013).
 
  •   Humalog is protected by a compound patent (2013).
 
  •   Strattera is protected by a patent covering its use in treating attention deficit-hyperactivity disorder (2016).
 
  •   Xigris is protected by a product patent (2015).
 
  •   Zyprexa is protected by a compound patent (2011).
 
Worldwide, we sell all of our major products under trademarks that we consider in the aggregate to be important to our operations. Trademark protection varies throughout the world, with protection continuing in some countries as long as the mark is used, and in other countries as long as it is registered. Registrations are normally for fixed but renewable terms.
 
Our
Intellectual Property Portfolio


 



We consider intellectual property protection for certain
products, processes, and uses – particularly those
products discussed below – to be important to our
operations. For many of our products, in addition to the





-4-




 






compound patent we hold other patents on manufacturing
processes, formulations, or uses that may extend exclusivity
beyond the expiration of the product patent.


 



The most relevant U.S. patent protection, together with
expected expiration, for our major marketed products is as
follows:


 










































































































  •  
Alimta is protected by a compound patent (2016).
 
  •  
Byetta is protected by a patent covering its use in
treating type 2 diabetes (2017).
 
  •  
Cialis is protected by compound and use patents
(2017).
 
  •  
Cymbalta is protected by a compound patent
(2013) and a composition patent (2014).
 
  •  
Evista is protected by patents on the treatment and
prevention of osteoporosis (2012 and 2014), and its dosage form
(2017). Evista for use in breast cancer risk reduction is
protected by orphan drug exclusivity (2014).
 
  •  
Gemzar is protected by a compound patent
(2010) and a patent covering its antineoplastic use (2013).
 
  •  
Humalog is protected by a compound patent (2013).
 
  •  
Strattera is protected by a patent covering its use
in treating attention deficit-hyperactivity disorder (2016).
 
  •  
Xigris is protected by a product patent (2015).
 
  •  
Zyprexa is protected by a compound patent (2011).


 



Worldwide, we sell all of our major products under trademarks
that we consider in the aggregate to be important to our
operations. Trademark protection varies throughout the world,
with protection continuing in some countries as long as the mark
is used, and in other countries as long as it is registered.
Registrations are normally for fixed but renewable terms.


 




This excerpt taken from the LLY 10-K filed Feb 28, 2007.
Our Intellectual Property Portfolio
 
We consider intellectual property protection for certain products, processes, and uses – particularly those products discussed below – to be important to our operations. For many of our products, in addition to the compound patent we hold other patents on manufacturing processes, formulations, or uses that may extend exclusivity beyond the expiration of the product patent.


-4-

 

 
We have the following U.S. patent protection for major marketed products:
 
  •   Alimta. We expect the U.S. compound patent for Alimta will expire in 2016.
 
  •   Byetta. Relevant patents covering Byetta are exclusively licensed or owned by our partner Amylin Pharmaceuticals, Inc. A method of use patent focused on the treatment of type 2 diabetes is expected to expire in the U.S. in 2017. In addition, a patent covering the Byetta formulation will expire in the U.S. in 2020.
 
  •   Cialis. For Cialis, compound and method-of-use patent protection exists in the U.S. that should provide exclusivity until 2017.
 
  •   Cymbalta. For Cymbalta, we expect the U.S. compound patent will expire in 2013. We also have a formulation patent for Cymbalta until 2014.
 
  •   Evista. We hold a number of U.S. patents covering Evista and its approved uses in osteoporosis prevention and treatment that we believe should provide us exclusivity in the United States until 2014.
 
  •   Gemzar. The Gemzar compound patent in the U.S. expires in 2010, and a method-of-use patent covering treatment of neoplasms with Gemzar is in force until 2012. We have also received an additional six months of marketing exclusivity for Gemzar from the FDA under the terms of the Food and Drug Administration Modernization Act of 1997, as a result of our conducting clinical studies of Gemzar in pediatric populations, which should provide us exclusivity until 2013.
 
  •   Humalog. The Humalog compound patent will expire in 2013.
 
  •   Strattera. For Strattera, a method-of-use patent in the U.S. for treating attention deficit-hyperactivity disorder should provide exclusivity until 2016.
 
  •   Xigris. Xigris is a complex glycoprotein biologic product that is produced through recombinant DNA technology. Xigris is not subject to the Abbreviated New Drug Application process under the Hatch-Waxman law as described below. In addition, we hold patents on the DNA materials, certain uses, manufacturing process, and the glycoprotein itself. We believe the intellectual property protection for Xigris should provide us marketing exclusivity in the U.S. until 2015.
 
  •   Zyprexa. The Zyprexa compound patent will expire in 2011.
 
Worldwide, we sell all of our major products under trademarks that we consider in the aggregate to be important to our operations. Trademark protection varies throughout the world, with protection continuing in some countries as long as the mark is used, and in other countries as long as it is registered. Registrations are normally for fixed but renewable terms.
 

EXCERPTS ON THIS PAGE:

10-K
Feb 22, 2010
10-K (2 sections)
Feb 27, 2009
10-K (2 sections)
Oct 21, 2008
10-K (2 sections)
Feb 29, 2008
10-K
Feb 28, 2007

RELATED TOPICS for LLY:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki